Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.42 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.42 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.39 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.39 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.39 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.39 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.39 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
| ▸ | PREP | P48147 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13340947 | 1.00 | POLB (0.49) | POLBPDK1PDK2PDK3PDK4 | |
| SCHEMBL8699830 | 1.00 | POLB (0.49) | POLBPDK1PDK2PDK3PDK4 | |
| SCHEMBL1058639 | 1.00 | POLB (0.49) | POLBPDK1PDK2PDK3PDK4 | |
| SCHEMBL30781570 | 0.91 | POLB (0.44) | POLBPDK1PDK2PDK3PDK4 | |
| SCHEMBL15341340 | 0.89 | PDK1 (0.45) | POLBPDK1PDK2PDK3PDK4 | |
| SCHEMBL5765411 | 0.87 | PDK1 (0.41) | POLBPDK1PDK2PDK3PDK4 | |
| SCHEMBL9384838 | 0.86 | ABCB1 (0.40) | POLBPDK1PDK2PDK3PDK4 | |
| SCHEMBL13297956 | 0.86 | ABCB1 (0.41) | POLBPDK1PDK2PDK3PDK4 | |
| SCHEMBL9386719 | 0.86 | PDK1 (0.40) | POLBPDK1PDK2PDK3PDK4 | |
| SCHEMBL5763557 | 0.85 | ECE1 (0.41) | POLBPDK1PDK2PDK3PDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026098315-A1 | HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2026-05-15 | — | — | WO | disclosed |
| EP-2839860-B1 | Pyrrolobenzodiazepines and conjugates thereof | MEDIMMUNE LTD (GB) | 2019-05-01 | — | — | EP | disclosed |
| US-20160376591-A1 | iRNA AGENTS WITH BIOCLEAVABLE TETHERS | BANK OF AMERICA, N.A. | 2016-12-29 | — | — | US | disclosed |
| US-9476045-B2 | iRNA agents with biocleavable tethers | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-10-25 | — | — | US | disclosed |
| US-20150073133-A1 | iRNA AGENTS WITH BIOCLEAVABLE TETHERS | BANK OF AMERICA, N.A. | 2015-03-12 | — | — | US | disclosed |
| EP-2839860-A1 | Pyrrolobenzodiazepines and conjugates thereof | Spirogen Sàrl (CH) | 2015-02-25 | — | — | EP | disclosed |
| EP-2839860-A1 | Pyrrolobenzodiazepines and conjugates thereof | Spirogen Sàrl (CH) | 2015-02-25 | — | — | EP | disclosed |
| US-8865677-B2 | iRNA agents with biocleavable tethers | ALNYLAM PHARMACEUTICALS, INC. (US) | 2014-10-21 | — | — | US | disclosed |
| WO-2014057074-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | SPIROGEN SÀRL (CH) | 2014-04-17 | — | — | WO | disclosed |
| US-8633185-B2 | Pyrrolobenzodiazepines | SPIROGEN SARL (CH) | 2014-01-21 | — | — | US | disclosed |
| US-20060148788-A1 | Pyrrolobenzodiazepines | SPIROGEN LIMITED (GB) | 2006-07-06 | — | — | US | disclosed |
| EP-1675857-A2 | PYRROLOBENZODIAZEPINE DERIVATIVES, COMPOSITIONS COMPRISING THE SAME AND METHODS RELATED THERETO | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-07-05 | — | — | EP | disclosed |
| US-7067511-B2 | Pyrrolobenzodiazepines | SPIROGEN LIMITED (GB) | 2006-06-27 | — | — | US | disclosed |
| US-7049311-B1 | Pyrrolbenzodiazepines | SPIROGEN LIMITED (GB) | 2006-05-23 | — | — | US | disclosed |
| WO-2005040170-A2 | PYRROLOBENZODIAZEPINE DERIVATIVES, COMPOSITIONS COMPRISING THE SAME AND METHODS RELATED THERETO | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2005-05-06 | — | — | WO | disclosed |
| EP-1109812-B1 | PYRROLOBENZODIAZEPINES | SPIROGEN LTD (GB) | 2005-05-04 | — | — | EP | disclosed |
| EP-1413582-A1 | Dimeric pyrrolobenzodiazepines | Spirogen Limited (GB) | 2004-04-28 | — | — | EP | disclosed |
| US-20030120069-A1 | Pyrrolobenzodiazepines | SPIROGEN LIMITED (GB) | 2003-06-26 | — | — | US | disclosed |
| EP-1193270-B1 | Pyrrolobenzodiazepines | SPIROGEN LTD (GB) | 2003-05-14 | — | — | EP | disclosed |
| EP-1193270-A2 | Pyrrolobenzodiazepines | Spirogen Limited (GB) | 2002-04-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148788-A1 | Pyrrolobenzodiazepines | HCRTR2, MCHR2, CHRM5 | POLB 2012/4885PDK1 2323/4885PDK2 1867/4885 |
| US-20030120069-A1 | Pyrrolobenzodiazepines | CNR1, CBX2, CNR2 | POLB 720/4885PDK1 4078/4885PDK2 4104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.